Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 526 - 550 of 1286 in total

Acalabrutinib

To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic...
Approved
Investigational
Matched Description: … This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia ... [L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor …
Matched Categories: … Kinase Inhibitor …

Abarelix

Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Approved
Investigational
Withdrawn

Raltitrexed

Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
Approved
Investigational
Matched Description: … It is an inhibitor of thymidylate synthase. …

Rescinnamine

Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia.
Approved
Matched Description: … Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. …

Betrixaban

Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals...
Approved
Investigational

Maprotiline

Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used...
Approved
Investigational

Afatinib

Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations...
Approved
Matched Description: … Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available …
Matched Categories: … Kinase Inhibitor …

Nalidixic acid

Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Approved
Investigational
Matched Description: … It is an inhibitor of the A subunit of bacterial DNA gyrase. …

Edoxaban

Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated...
Approved
Matched Description: … Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor …

Ticlopidine

Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot...
Approved
Matched Description: … Ticlopidine is an effective inhibitor of platelet aggregation. …

Nialamide

Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.
Approved
Withdrawn

Sulbactam

Sulbactam is a beta (β)-lactamase inhibitor and a derivative of the basic penicillin nucleus. When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.
Approved
Matched Description: … Sulbactam is a beta (β)-lactamase inhibitor and a derivative of the basic penicillin nucleus. …

Clopidogrel

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral...
Approved
Matched Description: … Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and …
Matched Categories: … P2Y12 Platelet Inhibitor …

Fosnetupitant

In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form...
Approved

Repotrectinib

Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene. ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for...
Approved
Investigational
Matched Description: … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance …
Matched Categories: … Kinase Inhibitor …

Nitisinone

Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin.
Approved
Investigational
Matched Description: … Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. …
Matched Categories: … 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor …

Malathion

Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice. Malathion is an irreversible cholinesterase inhibitor and has low human toxicity.
Approved
Investigational
Matched Description: … Malathion is an irreversible cholinesterase inhibitor and has low human toxicity. …

Spectinomycin

An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Approved
Investigational
Vet approved

Edrophonium

A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
Approved
Matched Description: … A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis …

Nirogacestat

Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling. Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling...
Approved
Investigational
Matched Description: … Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment …

Pegcetacoplan

Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).[A235000,L34095] Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody eculizumab. Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to...
Approved
Matched Description: … Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria ... [A235000,A235005] Pegcetacoplan is a pegylated C3 inhibitor that can disrupt the processes leading to ... [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis …

Sonidegib

Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Approved
Investigational
Matched Description: … Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer …
Matched Categories: … Hedgehog Pathway Inhibitor …

Dorzolamide

Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. Unlike oral CA inhibitors, dorzolamide...
Approved
Matched Description: … Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor …

Trametinib

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib...
Approved
Matched Description: … is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor ... non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a BRAF inhibitor …
Matched Categories: … Kinase Inhibitor …

Orlistat

The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a...
Approved
Investigational
Matched Description: … [A229928] Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting …
Matched Categories: … Intestinal Lipase Inhibitor …
Displaying drugs 526 - 550 of 1286 in total